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Abstract
Introduction
Rifampicin has been used as adjunctive therapy in Staphylococcus aureus bacteraemia
(SAB) with a deep infection focus. However, data for prognostic impact of rifampicin therapy
is unestablished including the optimal initiation time point. We studied the impact of rifampi-
cin therapy and the optimal initiation time for rifampicin treatment on prognosis in methicillin-
sensitive S. aureus bacteraemia with a deep infection.
Methods
Retrospective, multicentre study in Finland including 357 SAB patients with a deep infection
focus. Patients with alcoholism, liver disease or patients who died within 3 days were ex-
cluded. Patients were categorised according to duration of rifampicin therapy and according
to whether rifampicin was initiated early (within 7 days) or late (7 days after) after the posi-
tive blood cultures. Primary end point was 90 days mortality.
Results
Twenty-seven percent of patients received no rifampicin therapy, 14% received rifampicin
for 1-13 days whereas 59% received rifampicin14 days. The 90 day mortality was; 26%
for patients treated without rifampicin, 16% for rifampicin therapy of any length and 10% for
early onset rifampicin therapy14 days. Lack of rifampicin therapy increased (OR 1.89,
p=0.026), rifampicin of any duration decreased (OR 0.53, p=0.026) and rifampicin therapy
14 days with early onset lowered the risk for a fatal outcome (OR 0.33, p<0.01) during
90 days follow-up.
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Conclusion
Rifampicin adjunctive therapy for at least 14 days and initiated within 7 days of positive
blood culture associated with improved outcome among SAB patients with a deep infection.
Introduction
Staphylococcus aureus is one of the most common pathogens in bacteraemic infections [1–3].
However, treatment results in S. aureus bacteraemia (SAB) have not been considerably im-
proved despite the introduction of new antibiotics [1]. Complications and mortality in SAB
have been related to methicillin-resistance [2,3] and haematogenous dissemination resulting
in deep infection foci like endocarditis [3,4]. In recent studies, deep infection foci have been
found in up to 80% of SAB patients [5,6]. Adjunctive rifampicin therapy has been explored as
a way of improving treatment results in SAB with deep infections [5,7–15] whereas only few
studies have evaluated the impact of adjunctive rifampicin therapy in SAB without a deep in-
fection focus [8,9]. Rifampicin may be potentially valuable in S. aureus infections due to its bac-
tericidal nature, high anti-staphylococcal activity and good biofilm penetrating capability [16–
18]. Conventionally S. aureus has been regarded primarily as an extracellular bacterium al-
though much data point towards possibilities of intracellular survival [19,20]. Intracellular
survival has been suggested to enhance haematogenous dissemination and to result in subpop-
ulation formation with reduced antibiotic susceptibility and relapse of S. aureus infection [19–
23]. Recently it was proposed that the capability of rifampicin to achieve high intracellular con-
centrations may be essential for eradication of intra-leucocyte S. aureus infections [21].
In most studies, rifampicin has been combined to a staphylococcal penicillin [7–9,24], a gly-
copeptide (vancomycin) [8,9,25,26] or to a fluoroquinolone [10–15] in patients with chronic
osteomyelitis, foreign body infections, endocarditis or other deep seated abscesses. These stud-
ies have been small in size including only from 14 to maximally 105 patients [7–15,24] and few
studies only have been controlled and randomized [8–11,25]. Accordingly, statistically signifi-
cantly higher cure rate with rifampicin treatment has been observed only in a few studies
[5,8,11,14]. Recently, a stratified meta-analysis regarding Staphylococcus aureus bacteraemic
patients only demonstrated a non-significant reduction in infection related deaths as a result of
adjunctive rifampicin therapy [27].
Monotherapy with rifampicin results in rapid resistance development and combination ther-
apy is a prerequisite for use of rifampicin in SAB [28,29]. Resistance development has been
observed in studies with methicillin-resistant S. aureus (MRSA) or heteroresistant vancomycin-
intermediate S. aureus (hVISA) [25,26,30,31]. In these studies, no positive prognostic effect of
rifampicin was observed. In one study, 56% of patients developed rifampicin resistance and in
each case the patient was bacteraemic at rifampicin initiation whereas none of the patients with
negative blood cultures at rifampicin initiation developed resistance [26]. In this study, adjunc-
tive rifampicin was associated with prolonged bacteraemia and poorer outcome which resulted
in recommendations to commence rifampicin first after clearance of bacteraemia [26]. A large
prospective study, primarily investigating the beneficial effect of a levofloxacin combination
therapy in methicillin-sensitive S. aureus (MSSA) bacteraemia, produced a post hoc analysis
with 331 patients on the effect of rifampicin on mortality. Rifampicin adjunctive therapy signifi-
cantly improved outcome in patients with a deep infection focus [5]. This study was, however,
not randomized, did not give an answer as to when rifampicin treatment should be started and
did not identify the minimum duration of rifampicin therapy needed for a positive prognostic
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impact. Therefore, we found it interesting to study if rifampicin including combination therapy
would affect the outcome in SAB patients with a deep infection focus and how the time point of
rifampicin onset would affect the results in a larger patient material.
Materials and Methods
Patients and data collection
Altogether 617 adult patients with at least one positive blood culture for S. aureus were identi-
fied. When accounting for the exclusion and inclusion criteria a total of 357 patients with a
deep infection focus were accepted for this retrospective study. Part of the patients had partici-
pated in our earlier prospective multicentre study including all five university and seven central
hospitals in Finland during January 1999 to May 1999 and January 2000 to August 2002 [5].
The material was further extended with all SAB cases identified retrospectively who were not
included into the previous prospective study between 1999–2002 [5] and all SAB patients be-
tween 2006–2007 from Helsinki University Central Hospital [6]. Two time-periods were in-
cluded to exclude any unknown temporary differences in personnel or treatment practices.
Data collection included age, gender, underlying diseases, McCabe’s classification on underly-
ing diseases [32], medication, severe sepsis, septic shock and intensive care unit (ICU) treat-
ment. Any infectious diseases specialist (IDS) consultation was documented. Infection foci
documentation were based on clinical suspicion solely or verified by bacteriological, radiologi-
cal or pathological findings. All antibiotic therapy including length and route of administration
were documented. Patients were followed for 90 days and primary outcome was mortality
at 90 days.
Exclusion criteria
NoMRSA cases were included. Patients suffering from alcoholism and acute or chronic liver
diseases were excluded. These conditions may induce elevated liver enzymes and liver failure
during rifampicin therapy. Thus these conditions carry a risk for a statistical bias as patients
with these conditions are unlikely to receive adjunctive rifampicin therapy. The mean time-
lapse between blood culture collection and positive blood culture results was 3 days and thus
patients with a fatal outcome within 3 days of blood culture collection were excluded in order
to allow for a fatal outcome before positive blood culture results and the possibility to initiate
rifampicin therapy.
Ethics statement
The trial was approved by The institutional review board of Helsinki University Central Hospital
and The Ethical committee of Helsinki University Central Hospital. A written informed consent
was provided by each patient.
Definitions
Modified Duke criteria were used to define endocarditis [33]. Deep infection foci included
pneumonia, endocarditis, purulent arthritis, osteomyelitis, deep-seated abscess and any for-
eign-body infection. IDS consultation within 7 days of positive blood cultures were categorized
as informal telephone consultation or formal bedside consultation [6]. Severe sepsis and septic
shock was classified as sepsis in combination with hypotension, hypoperfusion, or organ
failure [34].
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The length of antibiotic therapy
Patients were categorized according to duration of rifampicin therapy into four groups i) no ri-
fampicin therapy, ii) short rifampicin therapy (1–13 days), iii) long rifampicin therapy (14
days) and iv) rifampicin therapy of any length (including all patients having received rifampi-
cin therapy). Patients with rifampicin therapy for at least 14 days were further classified ac-
cording to whether onset of rifampicin therapy took place within 7 days (early onset) or 7 days
after (late onset) the positive blood culture for S. aureus. Rifampicin was administered 450 mg
once daily for patients under 50 kg and 600 mg once daily for patients over 50 kg in weight.
The standard antibiotic therapy was either cloxacillin, cefuroxime, ceftriaxone, vancomycin or
clindamycin. Fluoroquinolone and aminoglycoside served as additional antibiotic therapy. Flu-
oroquinolone therapy included either levo-, moxi- or ciprofloxacin. Aminoglycoside therapy
included either tobramycin or gentamicin.
Statistical analysis
Categorical variables were compared with Pearson’s X2-test and odd ratios [OR] of 95% confi-
dence intervals [CI] were calculated. Univariate factors with p<0.1 were entered into Cox re-
gression model to estimate factors predicting 90-day mortality. All tests were two-tailed with
p<0.05 as significant. SPSS version 12.0 [SPSS Inc., Chicago, IL, USA] was used.
Results
Patient characteristics
Altogether 617 SAB patients were identified. Patients with alcoholism or acute or chronic liver
disease and fatal outcome within three days were excluded and only patients with a deep infec-
tion focus were included. Furthermore, patients with MRSA bacteraemia were not included in
the study (n = 6). In total, 260 patients were excluded and altogether 357 patients were left for
the analyses (Fig 1). Ninety-six (27%) of all 357 patients were treated without adjunctive rifam-
picin, 50 (14%) patients received adjunctive rifampicin for 1–13 days (short therapy) whereas
211 (59%) received adjunctive rifampicin for14 days (long therapy) (Table 1). Table 1 pres-
ent basic characteristics between the various treatment groups. Patients treated with short
rifampicin therapy were more often males (OR 2.11, p<0.05) and had less often healthcare-
associated SAB (OR 0.41, p<0.05) as compared to patients treated without rifampicin. No sig-
nificant difference regarding age, chronic diseases according to McCabe0s classification and
severity of illness at blood culture collection were observed between patients treated with short
rifampicin therapy or no rifampicin therapy. The only difference between patients with short
and long rifampicin treatment was the lower number of patients with septic shock at blood cul-
ture collection time point in the long rifampicin treatment group (1% vs. 6%, p<0.05). Howev-
er, the total amount of patients with septic shock at blood culture collection time point was
only 6 (1.7%) (Table 1).
Antibiotic therapy
Altogether 99% of patients had intravenous antibiotic therapy that was effective in vitro against
the S. aureus blood isolate. Vancomycin was given empirically in only 2% of cases. No differ-
ence was observed in the standard antibiotic therapy given after the blood culture results
between the various rifampicin treatment groups (Table 1). Antistaphylococcal penicillin
(cloxacillin) was given to 208 (58%) patients whereas a non cell-wall active agent (clindamycin)
was used in only 1.7% of patients. Fluoroquinolone (levo-, moxi- or ciprofloxacin) as an addi-
tional antibiotic was provided to 186 (52%) of patients and no significant difference between
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the patients with no rifampicin therapy, short or long rifampicin therapy was observed. No sig-
nificant difference in aminoglycoside treatment was observed between the various treatment
groups (Table 1).
Deep infection foci and consultations
The vast majority of deep infection foci were verified by bacteriological, radiological or patho-
logical findings whereas only a few pneumonia cases (n = 5) were based on a clinical suspicion
only. Patients treated with short rifampicin therapy received more often bedside IDS consulta-
tion (OR 7.00, p<0.05) and had more endocarditis diagnosed (OR 3.47, p<0.01) as compared
to patients treated without rifampicin. When comparing patients with short rifampicin therapy
to patients with long rifampicin therapy no significant difference in distribution of bedside IDS
consultation or deep infection foci were observed. Altogether only 6% of the patients received
informal telephone IDS (Table 1).
Outcome
The total case fatality in 357 patients at 90 days was 18%. When comparing rifampicin therapy
of any length to no rifampicin therapy, no significant difference in case fatality was seen at
Fig 1. Study profile. Originally 617 patients with methicillin-sensitive S. aureus bacteraemia were
identified. Patients with methicillin-resistant S. aureus bacteraemia were not included in the study (n = 6).
The exclusion criteria were: patients with fatal outcome within 3 days of positive blood cultures, patients with
alcoholism, acute or chronic liver diseases and patients without a deep infection foci. In total, 260 patients
were excluded and altogether 357 patients were left for the analyses. Early initiation of rifampicin therapy was
defined as an initiation within 7 days of positive blood cultures whereas late initiation of rifampicin therapy was
defined as an initiation 7 days past positive blood cultures.
doi:10.1371/journal.pone.0122824.g001
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Table 1. Characteristics of 357 patients with methicillin-sensitive S. aureus bacteraemia (SAB) and a deep infection focus categorized according
to duration of rifampicin therapy.
Rifampicin therapy Short therapy vs. no
therapy
Long therapy vs. short
therapy
Variables No therapy
n = 96 (27)
Short therapy n = 50
(14)
Long therapy n = 211
(59)
OR (95% CI) p- value OR (95% CI) p- value
Male sex 46 (48) 33 (66) 139 (66) 2.11
(1.04–4.29)
<0.05 0.99
(0.52–1.91)
NS
Age >60 years 60 (63) 26 (52) 105 (50) 0.65
(0.33–1.29)
NS 0.91
(0.49–1.69)
NS
Healthy-nonfatal disease A 62 (65) 34 (68) 165 (78) 1.17
(0.56–2.41)
NS 1.69
(0.86–3.33)
NS
Ultimately-rapidly fatal disease A 34 (35) 16 (32) 46 (22) 0.86
(0.42–1.78)
NS 0.59
(0.30–1.17)
NS
Healthcare-associated SAB 68 (71) 25 (50) 107 (51) 0.41
(0.20–0.84)
<0.05 1.03
(0.56–1.91)
NS
Intensive care unit B 14 (15) 8 (16) 38 (18) 1.12
(0.43–2.87)
NS 1.15
(0.50–2.65)
NS
Severe sepsis B 4 (4) 5 (10) 14 (7) 2.56
(0.65–9.98)
NS 0.64
(0.22–1.87)
NS
Septic shock B 1 (1) 3 (6) 2 (1) 5.71
(0.58–56.6)
NS 0.19
(0.03–1.14)
<0.05
Formal bedside IDS
consultation C
84 (88) 49 (98) 194 (92) 7.00
(0.88–55.5)
<0.05 0.23
(0.03–1.79)
NS
Informal telephone IDS
consultationC
9 (9) 0 14 (7) — — — —
Cloxacillin, standard antibiotic 57 (59) 35 (70) 116 (55) 1.59
(0.77–3.31)
NS 0.52
(0.27–1.02)
NS
Cefuroxime, standard antibiotic 24 (25) 13 (26) 61 (29) 1.05
(0.48–2.31)
NS 1.16
(0.58–2.33)
NS
Ceftriaxone, standard antibiotic 8 (8) 0 16 (8) — — — —
Vancomycin, standard antibiotic 1 (1) 1 (2) 5 (2) 1.94
(0.12–31.7)
NS 1.19
(0.14–10.4)
NS
Clindamycin, standard antibiotic 3 (3) 0 3 (1) — — — —
Fluoroquinolone, additional
antibioticD
59 (61) 26 (52) 101 (48) 0.68
(0.34–1.36)
NS 0.85
(0.46–1.57)
NS
Aminoglycoside, additional
antibiotic E
9 (9) 10 (20) 42 (20) 2.42
(0.91–6.41)
NS 0.99
(0.46–2.15)
NS
Endocarditis F 8 (8) 12 (24) 42 (20) 3.47
(1.31–9.18)
<0.01 0.79
(0.38–1.64)
NS
Deep-seated abscess F 39(41) 23 (46) 117 (55) 1.25
(0.63–2.48)
NS 1.46
(0.79–2.71)
NS
Foreign body infection F 29 (30) 8 (16) 48 (23) 0.44
(0.18–1.05)
NS 1.55
(0.68–3.52)
NS
Septic arthritis or osteomyelitis F 39 (41) 28 (56) 98 (46) 1.86
(0.93–3.71)
NS 0.69
(0.37–1.28)
NS
SAB relapse G 2 (2) 0 2 (1) — — — —
Patients with alcoholism, acute or chronic liver diseases, lack of deep infection foci, MRSA bacteraemia (n = 6) or a fatal outcome within 3 days have
been excluded. Values are expressed as n (%). NS = non-signiﬁcant. Short rifampicin therapy 1–13 days. Long rifampicin therapy 14 days.
A Classiﬁcation according to McCabe and Jackson [32].
B Severity of illness at blood culture collection time point.
C Infectious diseases specialist (IDS) consultation.
D Fluoroquinolone: levo-, moxi- or ciproﬂoxacin.
E Aminoglycoside: tobramycin or gentamicin.
F Deep infection focus within 90 days follow-up.
G SAB relapse within 90 days of follow-up.
doi:10.1371/journal.pone.0122824.t001
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28 days (11% vs. 17%, p = 0.130) whereas patients with rifampicin treatment had significantly
lower mortality at 60 days (13% vs. 23%, p = 0.027) and at 90 days (16% vs. 26%, p = 0.026)
(Table 2, Fig 2).
The prognostic impact of rifampicin therapy and early or late onset of rifampicin therapy
was evaluated by univariate analysis and Cox regression analysis (Table 3). In univariate analy-
sis, parameters with positive prognostic impact were McCabes0s healthy-nonfatal underlying
conditions (OR 0.18, p<0.001), rifampicin therapy of any duration (OR 0.53, p = 0.026), rifam-
picin therapy14 days with early onset (OR 0.28, p<0.001) and formal bedside IDS consulta-
tion (OR 0.41, p = 0.029). Age>60 years (OR 3.02, p<0.001), McCabe0s ultimately-rapidly
fatal underlying diseases (OR 5.45, p<0.001), healthcare-associated SAB (OR 2.23, p = 0.006),
Table 2. Bacteraemic relapse and outcome of 357 patients with methicillin-sensitive S. aureus bacteraemia (SAB) and a deep infection focus cate-
gorized according to adjunctive rifampicin therapy.
Rifampicin therapy Any length of rifampicin therapy
vs. no rifampicin therapy
Variables No therapy n = 96 (27%) Therapy of any length n = 261 (73%) OR (95% CI) p- value
SAB relapse A 2 (2) 2 (<1) 0.40 (0.06–2.89) 0.349
Mortality, at 28 days 16 (17) 28 (11) 0.60 (0.31–1.17) 0.130
Mortality, at 60 days 22 (23) 35 (13) 0.51 (0.28–0.93) 0.027
Mortality, at 90 days 25 (26) 41 (16) 0.53 (0.30–0.93) 0.026
Patients with alcoholism, acute or chronic liver diseases, lack of deep infection foci, MRSA bacteraemia (n = 6) or a fatal outcome within 3 days have
been excluded. Values are expressed as n (%).
A SAB relapse within 90 days follow-up
doi:10.1371/journal.pone.0122824.t002
Fig 2. Kaplan-Meier analysis of 90 days survival in 307 Staphylococcus aureus bacteraemia patients
with a deep infection focus according to rifampicin therapy (Log-Rank 0.000). The exclusion criteria
were: patients with fatal outcome within 3 days of positive blood cultures, patients with alcoholism, acute or
chronic liver diseases and patients without a deep infection foci. Patients with methicillin-resistant S. aureus
bacteraemia were not included in the study (n = 6).
doi:10.1371/journal.pone.0122824.g002
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ICU treatment (OR 2.22, p = 0.013), severe sepsis (OR 3.12, p = 0.008), endocarditis (OR 2.11,
p = 0.019), lack of rifampicin therapy (OR 1.89, p = 0.026) and informal IDS telephone consul-
tation (OR 3.12, p = 0.008) were associated with negative prognosis. Gender, SAB relapse, fluo-
roquinolone therapy, aminoglycoside therapy and late onset of rifampicin therapy had no
significant prognostic impact in univariate analysis (Table 3). In Cox regression analysis, the
parameters age>60 years (OR 2.00, p = 0.017), severe sepsis (OR 3.64, p = 0.01), endocarditis
(OR 2.68, p = 0.01) and informal telephone consultation (OR 2.11, p = 0.04) had a negative
prognostic impact whereas McCabes0s healthy-nonfatal underlying condition (OR 0.23,
p<0.01) and rifampicin therapy14 days with early onset (OR 0.33, p<0.01) were markers of
positive prognosis (Table 3). In order to investigate whether patients who died early were sick-
er, and thus more likely to be treated without rifampicin, the analyses of Table 3 were repeated
by excluding patients with a fatal outcome within 21 days. The results of this Cox regression
analysis resembled those of Table 3 with a positive prognostic impact of early onset of rifampi-
cin therapy for14 days (OR 0.48, p<0.01).
Table 3. Cox regression analysis for prognostic factors according to 90-daymortality in 357 patients with methicillin-sensitive S. aureus bacterae-
mia (SAB) with at least one deep infection focus.
Univariate analysis Cox regression analysis 1
Survived N = 291 (82) Died N = 66 (18) OR (95% CI) p- value OR (95% CI) p- value
Male sex 181 (62) 37 (56) 0.78(0.45–1.33) NS — —
Age >60 years 142 (49) 49 (74) 3.02(1.66–5.49) <0.001 2.00(1.13–3.54) 0.017
Healthy-nonfatal disease A 233 (80) 28 (42) 0.18(0.10–0.32) <0.001 0.23(0.14–0.39) <0.01
Ultimately-rapidly fatal disease A 58 (20) 38 (58) 5.45(3.09–9.61) <0.001 — —
Healthcare associated SAB 153 (53) 47 (71) 2.23(1.25–3.99) 0.006 — —
Intensive care unit B 42 (14) 18 (27) 2.22(1.18–4.19) 0.013 — —
Severe sepsis B 14 (5) 9 (14) 3.12(1.29–7.57) 0.008 3.64(1.76–7.53) 0.01
Endocarditis C 44 (15) 18 (27) 2.11(1.12–3.95) 0.019 2.68(1.53–4.71) 0.01
Fluoroquinolone therapy D 156 (54) 30 (45) 0.72(0.42–1.23) NS — —
Aminoglucoside therapy 45 (15) 16 (24) 1.75(0.92–3.34) NS — —
Lack of rifampicin therapy 71 (24) 25 (38) 1.89(1.07–3.32) 0.026 — —
Rifampicin therapy of any duration E 220 (76) 41 (62) 0.53(0.30–0.93) 0.026 — —
Rifampicin therapy 14 days, early onset F 167 (57) 18 (27) 0.28(0.15–0.50) <0.001 0.33(0.19–0.57) <0.01
Rifampicin therapy 14 days, late onset G 22 (8) 4 (6) 0.79(0.26–2.37) NS — —
Bedside IDS consultation H 271 (93) 56 (84) 0.41(0.18–0.93) 0.029 — —
Telephone IDS consultation H 14 (5) 9 (14) 3.12(1.29–7.57) 0.008 2.11(1.01–4.42) 0.04
Patients with alcoholism, acute or chronic liver diseases, lack of deep infection foci, MRSA bacteraemia (n = 6) or a fatal outcome within 3 days have
been excluded. Values are expressed as N (%) and odds ratio (OR) for fatal outcome within 90 days. NS = non-signiﬁcant.
1 Cox regression analysis results are shown only for parameters with signiﬁcant prognostic impact (p<0.05).
A Classiﬁcation according to McCabe and Jackson [32].
B Severity of illness at blood culture collection time point
C Endocarditis diagnosed within 90 days follow-up.
D Fluoroquinolone: levo-, moxi- or ciproﬂoxacin.
E Including all patients with rifampicin therapy of any length.
F Early onset i.e. onset within 7 days of positive blood culture.
G Late onset i.e. onset 7 days after positive blood culture.
H Infectious diseases specialist (IDS) consultation
doi:10.1371/journal.pone.0122824.t003
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Discussion
The main finding of this study was a potential positive prognostic impact due to adjunctive ri-
fampicin therapy in patients with a deep infection focus in methicillin-sensitive SAB. During
the follow-up time period of 90 days, the mortality among patients treated with adjunctive ri-
fampicin therapy for at least 14 days started during the first week of the positive blood culture
was ten percent whereas the mortality for patients treated without rifampicin therapy during
the corresponding time period was twenty-six percent. Early onset adjunctive rifampicin thera-
py for at least 14 days decreased the risk of fatal outcome to one third in Cox
regression analysis.
Our study demonstrating significantly improved treatment results with rifampicin combi-
nation therapy in SAB with a deep infection focus is in line with previous studies [8,11,14] and
studies showing a non-significant tendency towards better treatment result with rifampicin
[7,9,10,15]. In common to most of these studies has been a low MRSA prevalence. In contrast
to many previous studies, we only analysed mortality as the main outcome parameter. Rifampi-
cin adjunctive therapy did not influence SAB relapse although this conclusion has to be made
with a great caution due to the low occurrence of SAB relapses in our material. Early mortality,
i.e. mortality during the 3 first days, was excluded from the analysis to be able to see the unbi-
ased effect of rifampicin therapy on outcome.
Studies of rifampicin combination therapy in SAB with high MRSA prevalence (76–100%)
have reported poorer clinical outcome due to rifampicin combination [25,26,30,31]. In a pro-
spective report of MRSA native valve endocarditis, rifampicin-vancomycin therapy resulted in
non-significantly prolonged bacteraemia as compared to vancomycin only [25]. A retrospec-
tive study investigated the benefit of adjunctive rifampicin therapy in native valve endocarditis
with a high MRSA prevalence (76%) and showed prolonged bacteraemia and a significant neg-
ative prognostic impact for patients receiving rifampicin therapy [26]. Delay in effective antibi-
otic therapy may result in worse outcome in SAB [35]. MRSA has been associated with delayed
effective antibiotic therapy and worse prognosis as compared to MSSA [2]. The present study
included only MSSA cases and 99% of patients received effective intravenous antibiotic therapy
from the first day of the blood culture collection. Invasive and bacteraemic infections due to
MRSA are rare in Finland with MRSA prevalence remaining near 3% [36]. Vancomycin has
been shown to increase the tendency for bacteraemia persistence and recurrence as compared
to antistaphylococcal penicillin cloxacillin [37]. Vancomycin was provided to only 2% of our
patients. Thus, the impact of rifampicin therapy on outcome could be evaluated without distur-
bance from delayed empirical antibiotic therapy. However, our study gives no answer on the
value of rifampicin combination therapy in MRSA bacteraemia.
No data is available on the optimal timing of adjunctive rifampicin therapy initiation along-
side standard antibiotic treatment. In MRSA bacteraemia, early rifampicin treatment was asso-
ciated with emergence of resistance in 37–56% of cases when rifampicin was started during the
bacteraemic phase [26,30,31]. In one study, each case of rifampicin resistance was due to thera-
py started during the bacteraemic phase whereas no resistance developed when rifampicin was
initiated subsequent to bacteraemia clearance [26]. One report compared MRSA and hVISA
bacteraemic patients who were receiving rifampicin-vancomycin therapy and demonstrated
prolonged bacteraemia and higher rifampicin-resistance development for hVISA cases. Due to
hVISA, the vancomycin serum concentration was below the required hVISA MIC and the au-
thors interpreted this as rifampicin monotherapy resulting in the development of rifampicin
resistance [30]. Hence, the development of rifampicin resistance in MRSA bacteraemia might
be related to relative weak anti-staphylococcal effect or problems in tissue penetration of van-
comycin or to longer persistence of bacteraemia during vancomycin therapy rather than due to
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methicillin-resistance of the staphylococcal strain [37,38]. Follow-up blood cultures were not
routinely taken in our patient cohort and the present study does not give an answer on the
question of possibility of rifampicin resistant development in MSSA bacteraemia.
In the present study, the median time from blood culture to clinical awareness of S. aureus
being the causative pathogen was 3 days in average. In practice, rifampicin treatment was com-
menced earliest at this time point i.e. 3 days subsequent to effective empirical antimicrobial
therapy, mostly a beta-lactam. Our results clearly point to a positive prognostic impact when
rifampicin treatment is started during the first week of positive blood culture. Altogether the
present study included 26 patients with a deep infection focus in which rifampicin was started
later than 7 days past positive blood culture and continued for longer than 14 days. Among
these patients rifampicin treatment showed no signs of improved prognosis. However, these re-
sults have to be interpreted with great caution due to the small patient number (n = 26) and the
retrospective nature of this study. Once started, rifampicin therapy is usually continued for sev-
eral weeks [38]. The patient group who received rifampicin therapy shorter that 14 days was
also too small (n = 50) for rigorous and detailed analysis. Thus, no firm conclusions and no rec-
ommendations concerning a lack of prognostic influence of short rifampicin therapy or late
started rifampicin therapy (14 days) can be made. Future randomized controlled trials with
higher patient numbers are needed both to confirm our findings and to give an answer to
whether later onset or shorter rifampicin treatment will have any prognostic impact.
The present study did not investigate the impact of different rifampicin dosages or the im-
pact of administration routes on prognosis. Rifampicin was administered 450 mg once daily
for patients under 50 kg and 600 mg once daily for patients over 50 kg in weight. This dosage,
however, is far lower than that used in some studies e.g. 450 mg every 12 hours [11] or 20mg/
kg given in divided doses twice a day without exceeding daily doses of 1800 mg [14]. The po-
tential positive prognostic impact associated with adjunctive rifampicin therapy for at least 14
days observed in the present study might have been stronger with higher rifampicin doses.
The present study excluded patients with a fatal outcome within 3 days in order to allow for
death before positive blood culture results and the possibility to receive rifampicin therapy. It could
be argued that patients who died early were more ill and thus more likely to be treated without ri-
fampicin. However, as a subanalysis the Cox regression was performed by excluding patients with a
fatal outcome within 21 days and the results were very similar to the main Cox regression analysis
with early onset of rifampicin therapy for at least 14 days associating to positive prognosis.
Also other attempts were made to control reasons for the difference in outcome between the
groups. Most of the factors with prognostic impact in this study have been identified earlier e.g.
age [3,39,40], McCabe0s classification [3], endocarditis [3,39] and IDS consultation [3,6]. Pa-
tients treated without rifampicin therapy were less often males and had more often healthcare-
associated SAB. The present study can not provide any clear explanation for this gender distri-
bution. Healthcare-associated SAB has been associated to poorer SAB outcome [39], however,
when controlling for all of these factors, early onset rifampicin therapy for at least 14 days still
remained a favourable prognostic factor (OR 0.33, p<0.01). Case fatality in our material was
only 18% at 90 days follow-up which is at the lower end compared to many other SAB studies
[3,40,41,42]. The low mortality has most probably decreased the power to detect a positive
prognostic effect of rifampicin.
SAB patients with alcoholism and acute or chronic liver diseases were excluded from our
main patient cohort. The risk for liver failure as a complication for rifampicin therapy is strongly
accentuated in patients with alcoholism or liver diseases and these conditions are viewed as con-
traindications for rifampicin [43]. Alcoholism and liver diseases unavoidably creates a statistical
bias as patients with these conditions are very unlikely to receive rifampicin therapy.
Improved Staphylococcus aureus Bacteraemia Outcome with Rifampicin
PLOS ONE | DOI:10.1371/journal.pone.0122824 April 13, 2015 10 / 13
In conclusion, despite the retrospective nature of the present study the results indicated that
in MSSA bacteraemia patients with a deep infection focus may gain from adjunctive rifampicin
therapy of at least 14 days of length when rifampicin is initiated within 7 days of positive blood
culture. Recommendations on rifampicin combination with other antimicrobial regimens in
MRSA bacteraemia cannot be made based on the results of the present study and prospective
randomized studies on the effect of rifampicin combination in MSSA and MRSA bacteraemia
are needed.
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